KRYS vs. FXAIX

Last updated Apr 2, 2026

Compare and contrast key facts about Krystal Biotech, Inc. (KRYS) and Fidelity 500 Index Fund (FXAIX).

FXAIX is a passively managed fund by Fidelity that tracks the performance of the S&P 500 Index. It was launched on Feb 17, 1988.

Performance

KRYS vs. FXAIX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Krystal Biotech, Inc. (KRYS) and Fidelity 500 Index Fund (FXAIX). The values are adjusted to include any dividend payments, if applicable.

KRYS vs. FXAIX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
KRYS Krystal Biotech, Inc.	5.02%	57.37%	26.28%	56.60%	13.25%	16.58%	8.34%	166.51%	97.53%	-1.13%
FXAIX Fidelity 500 Index Fund	-4.34%	17.84%	25.01%	26.29%	-18.14%	28.71%	18.42%	31.48%	-4.43%	7.16%

Returns By Period

In the year-to-date period, KRYS achieves a 5.02% return, which is significantly higher than FXAIX's -4.34% return.

KRYS

• 1D: 0.23%
• 1M: 0.04%
• YTD: 5.02%
• 6M: 44.15%
• 1Y: 48.30%
• 3Y*: 47.88%
• 5Y*: 27.54%
• 10Y*: —

FXAIX

• 1D: 2.92%
• 1M: -5.02%
• YTD: -4.34%
• 6M: -2.14%
• 1Y: 17.32%
• 3Y*: 18.30%
• 5Y*: 11.79%
• 10Y*: 14.08%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

KRYS vs. FXAIX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KRYS

KRYS Risk / Return Rank: 70
KRYS Sharpe Ratio Rank: 77
KRYS Sortino Ratio Rank: 69
KRYS Omega Ratio Rank: 70
KRYS Calmar Ratio Rank: 68
KRYS Martin Ratio Rank: 66

FXAIX

FXAIX Risk / Return Rank: 60
FXAIX Sharpe Ratio Rank: 48
FXAIX Sortino Ratio Rank: 53
FXAIX Omega Ratio Rank: 56
FXAIX Calmar Ratio Rank: 64
FXAIX Martin Ratio Rank: 76

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KRYS vs. FXAIX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and Fidelity 500 Index Fund (FXAIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KRYS	FXAIX	Difference
Sharpe ratio Return per unit of total volatility	1.14	0.97	+0.17
Sortino ratio Return per unit of downside risk	1.61	1.49	+0.12
Omega ratio Gain probability vs. loss probability	1.22	1.23	-0.01
Calmar ratio Return relative to maximum drawdown	1.37	1.52	-0.15
Martin ratio Return relative to average drawdown	2.98	7.30	-4.31
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KRYS vs. FXAIX - Sharpe Ratio Comparison

The current KRYS Sharpe Ratio is 1.14, which is comparable to the FXAIX Sharpe Ratio of 0.97. The chart below compares the historical Sharpe Ratios of KRYS and FXAIX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	KRYS	FXAIX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.14	0.97	+0.17
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.36	0.70	-0.34
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.78	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.61	0.76	-0.15

Correlation

The correlation between KRYS and FXAIX is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

KRYS vs. FXAIX - Dividend Comparison

KRYS has not paid dividends to shareholders, while FXAIX's dividend yield for the trailing twelve months is around 1.16%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
KRYS Krystal Biotech, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
FXAIX Fidelity 500 Index Fund	1.16%	1.11%	1.25%	1.45%	1.69%	1.22%	1.60%	2.06%	2.72%	1.97%	2.52%	2.83%

Drawdowns

KRYS vs. FXAIX - Drawdown Comparison

The maximum KRYS drawdown since its inception was -53.42%, which is greater than FXAIX's maximum drawdown of -33.79%. Use the drawdown chart below to compare losses from any high point for KRYS and FXAIX.

Drawdown Indicators

	KRYS	FXAIX	Difference
Max Drawdown Largest peak-to-trough decline	-53.42%	-33.79%	-19.63%
Max Drawdown (1Y) Largest decline over 1 year	-31.85%	-12.13%	-19.72%
Max Drawdown (5Y) Largest decline over 5 years	-51.34%	-24.50%	-26.84%
Max Drawdown (10Y) Largest decline over 10 years	—	-33.79%	—
Current Drawdown Current decline from peak	-11.31%	-6.23%	-5.08%
Average Drawdown Average peak-to-trough decline	-16.43%	-3.83%	-12.60%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.61%	2.53%	+12.08%

Volatility

KRYS vs. FXAIX - Volatility Comparison

Krystal Biotech, Inc. (KRYS) has a higher volatility of 9.78% compared to Fidelity 500 Index Fund (FXAIX) at 5.34%. This indicates that KRYS's price experiences larger fluctuations and is considered to be riskier than FXAIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KRYS	FXAIX	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.78%	5.34%	+4.44%
Volatility (6M) Calculated over the trailing 6-month period	25.71%	9.53%	+16.18%
Volatility (1Y) Calculated over the trailing 1-year period	42.66%	18.32%	+24.34%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	76.66%	16.92%	+59.74%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.80%	18.05%	+56.75%